A similar case reported by Feola et al9 described a PASH syndrome with an atypical Mediterranean fever gene (MEFV) mutation that responded well to adalimumab, further supporting the therapeutic rationale. This evidence concerns the gene MEFV and Pyoderma gangrenosum-acne-suppurative hidradenitis syndrome.